{
  "pmcid": "6939293",
  "sha256": "acd5736a78d7c0f9e9bf1ee5f6c231c402e417bae3da86132baf6d8af6439278",
  "timestamp_utc": "2025-11-09T22:52:32.723250+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.354348646947766,
    "reading_ease": 40.08007342143907,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Operator Radiation Exposure in Transcatheter Valve Implantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, operators wore dosimeters during TAVR-TF (n = 50) and TAVR-AA (n = 31) procedures."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Disposable radiation shielding pads (RADPAD) or a placebo were used in a blinded manner."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare operator radiation exposure during transcatheter aortic valve replacement (TAVR) via transfemoral (TF) and alternative access (AA) approaches, and to assess the impact of disposable shielding."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was operator radiation exposure, measured in mRad."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Disposable radiation shielding pads (RADPAD) or a placebo were used in a blinded manner."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "TAVR-TF (n = 50) and TAVR-AA (n = 31) procedures."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Operator radiation exposure was significantly higher in TAVR-AA compared to TAVR-TF (median 15.1 mRad [IQR 8.6, 32.4] vs 5.5 mRad [IQR 2.4, 9.8], P < .001)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}